ZIOPHARM ONCOLOGY INC

Form 4

January 14, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average

burden hours per

response...

0.5

OMB APPROVAL

Section 16. Form 4 or Form 5 obligations may continue.

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

See Instruction

1. Name and Address of Reporting Person *

KIRK RANDAL J

2. Issuer Name and Ticker or Trading

Symbol

ZIOPHARM ONCOLOGY INC

5. Relationship of Reporting Person(s) to

Issuer

[ZIOP]

01/12/2011

3. Date of Earliest Transaction

(Month/Day/Year)

(Check all applicable) _X__ Director

Officer (give title

X__ 10% Owner Other (specify

C/O THIRD SECURITY, LLC, 1881

(State)

(First)

GROVE AVENUE

(Street) 4. If Amendment, Date Original

(Middle)

(Zin)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

RADFORD, VA 24141

(City)	(State)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) DOOR Disposed of (D) (Instr. 3, 4 and 5) (A)		5. Amount of Securities Ownership Beneficially Form: Owned Direct (D) Following or Indirect Reported (I) Transaction(s) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	01/12/2011		A	25,000 (1)	A	\$ 0	25,000	D	
Common Shares	01/12/2011		P	2,426,235	A	\$ 4.8	2,426,235	I	By Intrexon Corporation
Common Stock	01/12/2011		P	3,636,926	A	(3)	6,063,161	I	By Intrexon Corporation

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 5.21	01/12/2011		A	25,000	<u>(4)</u>	01/12/2021	Common Stock	25,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting owner rune, runers	Director	10% Owner	Officer	Other		
KIRK RANDAL J C/O THIRD SECURITY, LLC 1881 GROVE AVENUE RADFORD, VA 24141	X	X				
INTREXON CORP C/O LEGAL DEPARTMENT 20358 SENECA MEADOWS PARKWAY GERMANTOWN, MD 20876		X				
Signatures						
/s/ Randal J. Kirk	01/14/2011					
**Signature of Reporting Person		Date				
/s/ Randal J. Kirk, CEO of Intrexon Corporation		01/14/2011				
**Signature of Reporting Person		Date				

Reporting Owners 2

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All restrictions related to the grant of restricted stock will lapse on January 12, 2012.
- Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of (2) Intrexon Corporation. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon Corporation. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- (3) Shares were issued as partial consideration in connection with the execution of an Exclusive Channel Partner Agreement dated January 6, 2011 between the issuer and Intrexon Corporation.
- Option to purchase shares of common stock will vest over a three (3) year period as follows: 8,334 shares on January 12, 2012; 8,333 shares on January 12, 2013; and 8,333 shares on January 12, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.